Loading…
Prestige Consumer Healthcare Inc. is projected to rise to $54.06 by 2027, a +12% move from its current price of $48.27. PBH is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $47.46 | $48.29 | $49.13 | +0.04% |
| May 30 | $47.14 | $48.31 | $49.50 | +0.08% |
| May 31 | $46.90 | $48.33 | $49.79 | +0.12% |
| Jun 1 | $46.70 | $48.34 | $50.04 | +0.15% |
| Jun 2 | $46.53 | $48.36 | $50.26 | +0.19% |
| Jun 3 | $46.38 | $48.38 | $50.47 | +0.23% |
| Jun 4 | $46.24 | $48.40 | $50.66 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $46.24 | $48.40 | $50.66 | +0.27% |
| Week 2 | $45.50 | $48.53 | $51.77 | +0.54% |
| Week 3 | $44.96 | $48.66 | $52.66 | +0.81% |
| Week 4 | $44.53 | $48.79 | $53.45 | +1.08% |
| Week 5 | $44.18 | $48.92 | $54.18 | +1.35% |
| Week 6 | $43.86 | $49.05 | $54.86 | +1.62% |
| Week 7 | $43.59 | $49.18 | $55.50 | +1.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Prestige Consumer Healthcare Inc. develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
The portfolio spans analgesics, skin care, throat relief, eye care, wart removal, dental care, motion sickness relief, laxatives, stomach remedies, cough drops, yeast infection care, lice treatments, feminine care, dry eye products, nasal saline products, and oral rehydration products. Prestige markets its products to mass merchandisers, drug, food, dollar, convenience, and club stores, as well as e-commerce channels.
Prestige was founded in 1996 and is headquartered in Tarrytown, New York. It was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018.
PBH is currently priced at $48.00 per share and has a market capitalization of $2.27B. It ranks 1911 in market cap among peers.
The price outlook implied by the forecast shows a near-term neutral stance in 2026, with an average price of $48.00, a low of $45.93, and a high of $60.72, and a 0% ROI. From 2027 onward, the forecast turns more bullish, with the average price rising to $53.96 in 2027 and $54.34 in 2028, then continuing higher to $58.81 in 2029 and $66.31 in 2030, extending to $236.00 by 2050. The longest horizon projects a strong upside with peak averages and ROIs in later years (2031–2050), reaching $72.48, $84.36, $90.88, $90.37, $94.70 in the 2030s–2035 period, and $144.90 in 2040, $236.00 in 2050, with ROIs climbing from 12.4% to 391.7% as the years advance.
A major floor 21.2% below — a decisive break under it would weaken the trend.
The nearest floor, 4.8% below — buyers have tended to step in here.
The nearest ceiling, 22.1% above — a clean break opens room to run.
A major ceiling 45.5% above — clearing it would confirm fresh momentum.
Key PBH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PBH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $47.94 | Buy | $48.01 | Buy |
| MA 10 | $47.72 | Buy | $48.57 | Sell |
| MA 20 | $50.91 | Sell | $50.50 | Sell |
| MA 50 | $55.38 | Sell | $54.73 | Sell |
| MA 100 | $60.59 | Sell | $58.29 | Sell |
| MA 200 | $61.55 | Sell | $62.43 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.70 | Neutral |
| Stoch RSI (14) | 84.37 | Sell |
| CCI (20) | -52.51 | Neutral |
| Williams %R (14) | -72.98 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -8.13 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 27.02 | Neutral |
| TRIX (15) | -0.68 | Sell |
| Awesome (5,34) | -5.73 | Sell |
| Ultimate (7,14,28) | 58.73 | Neutral |
| Momentum (10) | -2.14 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 48.44 | Sell |
| ADX (14) | 30.62 | Sell |
| ATR (14) | 0.93 | Info |
The 30-day technical picture is bearish, with RSI(14) at 30, suggesting potential oversold conditions near-term.
The 50-day simple moving average sits at $55.90 and the 200-day simple moving average at $61.74, placing the current price below both indicators. The stock trades within a 30-day range of $42.54 to $54.16, and key near-term levels are a support at $45.93 and a resistance at $58.94. Annualized volatility sits around 30%, underscoring notable price movement potential in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $45.93 | $48.27 | $60.92 | 0% | Neutral | |
| $44.16 | $54.06 | $69.27 | +12% | Neutral | |
| $43.81 | $54.61 | $71.80 | +13% | Neutral | |
| $46.47 | $58.80 | $78.91 | +22% | Bullish | |
| $51.65 | $66.22 | $90.45 | +37% | Bullish | |
| $56.03 | $72.71 | $100.86 | +51% | Bullish | |
| $64.05 | $84.04 | $118.22 | +74% | Bullish | |
| $68.37 | $90.66 | $129.16 | +88% | Bullish | |
| $67.90 | $90.92 | $131.07 | +88% | Bullish | |
| $69.81 | $94.35 | $137.51 | +95% | Bullish | |
| $102.89 | $145.02 | $221.43 | +200% | Bullish | |
| $155.38 | $234.84 | $384.26 | +387% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $45.93 | $48.27 | $56.60 | +0.00% |
| June 2026 | $42.63 | $49.73 | $59.14 | +3.03% |
| July 2026 | $42.60 | $49.99 | $60.01 | +0.51% |
| August 2026 | $42.03 | $49.53 | $59.89 | -0.91% |
| September 2026 | $42.62 | $50.42 | $61.33 | +1.80% |
| October 2026 | $43.15 | $51.21 | $62.63 | +1.57% |
| November 2026 | $42.14 | $50.17 | $61.64 | -2.04% |
| December 2026 | $41.34 | $49.36 | $60.92 | -1.61% |
Click any year to see its month-by-month PBH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, PBH could reach as high as $60.92, with a base case around $48.27 and support toward $45.93 — roughly 0% from $48.27. A consolidation phase looks the most probable path here.
Expect PBH to range from $44.16 to $69.27 through 2027. The $54.06 average target implies a +12% move from current prices. That is up +12% on the projected 2026 average. Price action looks broadly range-bound.
The PBH price prediction for 2028 points to an average of $54.61 (low $43.81, high $71.80) — a potential gain of +13% on today's $48.27. A consolidation phase looks the most probable path here.
In 2029, PBH is projected to trade between $46.47 and $78.91, averaging $58.80 — a potential gain of +22% from today's $48.27. That is up +8% on the projected 2028 average. Momentum favours further upside here.
Prestige Consumer Healthcare Inc.'s 2030 outlook centres on $66.22, within a $51.65 to $90.45 range. That is up +13% on the projected 2029 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, PBH could reach as high as $100.86, with a base case around $72.71 and support toward $56.03 — roughly +51% from $48.27. Momentum favours further upside here.
Expect PBH to range from $64.05 to $118.22 through 2032. The $84.04 average target implies a +74% move from current prices. That is up +16% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The PBH price prediction for 2033 points to an average of $90.66 (low $68.37, high $129.16) — a potential gain of +88% on today's $48.27. Momentum favours further upside here.
In 2034, PBH is projected to trade between $67.90 and $131.07, averaging $90.92 — a potential gain of +88% from today's $48.27. That is up 0% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Prestige Consumer Healthcare Inc.'s 2035 outlook centres on $94.35, within a $69.81 to $137.51 range. That is up +4% on the projected 2034 average. That marks a +95% change versus current levels. Momentum favours further upside here.
By 2040, PBH could reach as high as $221.43, with a base case around $145.02 and support toward $102.89 — roughly +200% from $48.27. Buyers look set to stay in control over this stretch.
Expect PBH to range from $155.38 to $384.26 through 2050. The $234.84 average target implies a +387% move from current prices. That is up +62% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PBH today (≈ 20.716801 PBH) could be worth
$4,865.15
+$3,865.15 (+387%) by 2050 · US Dollar
Based on the average projected PBH price of $234.84 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PBHwould be worth at today's price.
$1,000 invested in PBH on May 27, 2025 (≈ 11.644155 PBH) would be worth
$562.06
-$437.94 (-43.8%) today · 0.56× · US Dollar
Based on a PBH entry price of $85.88 vs. today's $48.27.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $47.19 | $1,022.89 | +2.3% |
| 1 month ago | $58.3 | $827.96 | -17.2% |
| 3 months ago | $70.21 | $687.51 | -31.2% |
| 6 months ago | $59.55 | $810.58 | -18.9% |
| 1 year ago | $85.88 | $562.06 | -43.8% |
| All time (5.0y) ago | $49.93 | $966.75 | -3.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PBH forecast.
Our base-case forecast reaches $97.00 around 2040.
Implied market cap at $97.00: $4.6B
Over the multi-year horizon, the forecast paints a bullish trajectory, with average prices rising from the late-2020s into the 2030s and beyond. For 2029 the avg is $58.81 and by 2030 the avg reaches $66.31, with a 2030 ROI of 38.1%. The 2031–2035 window shows continued gains: 2031 avg $72.48 (ROI 51), 2032 avg $84.36 (ROI 75.8), 2033 avg $90.88 (ROI 89.3), 2034 avg $90.37 (ROI 88.3), and 2035 avg $94.70 (ROI 97.3%), all with bullish sentiment.
The longer horizon strengthens substantially: 2040 avg $144.90 (ROI 201.9%) and 2050 avg $236.00 (ROI 391.7%), with corresponding bullish sentiment. These figures indicate a steadily rising price path and progressively larger ROI over time, though they are not guarantees and depend on future conditions and market factors. Risk and uncertainty remain inherent in any forecast.
Tap a question to reveal the answer.
2030: min $51.70, avg $66.31, max $90.59; ROI 38.1%; sentiment BULLISH.
The forecast shows a bullish long-term path, with 2050 avg $236.00 and ROI 391.7%, though near-term 2026 is NEUTRAL. Key middle years show gradual gains (e.g., 2027 avg $53.96, 2028 avg $54.34, 2029 avg $58.81).
Yes. The forecast lists 2031 max $100.57.
Current price $48.00; market cap $2.27B; rank 1911.
30-day range: low $42.54, high $54.16.
Prestige Consumer Healthcare Inc. Community Discussion
0Share your Prestige Consumer Healthcare Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.